ATE553198T1 - Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten - Google Patents
Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitätenInfo
- Publication number
- ATE553198T1 ATE553198T1 AT06750227T AT06750227T ATE553198T1 AT E553198 T1 ATE553198 T1 AT E553198T1 AT 06750227 T AT06750227 T AT 06750227T AT 06750227 T AT06750227 T AT 06750227T AT E553198 T1 ATE553198 T1 AT E553198T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- proteasome
- treatment
- combined inhibition
- telomerase
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 title 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 title 1
- 108010017842 Telomerase Proteins 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 2
- 229940123582 Telomerase inhibitor Drugs 0.000 abstract 2
- 239000003207 proteasome inhibitor Substances 0.000 abstract 2
- 239000003277 telomerase inhibitor Substances 0.000 abstract 2
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002301 combined effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000005713 exacerbation Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67163005P | 2005-04-15 | 2005-04-15 | |
| PCT/US2006/014137 WO2006113470A2 (en) | 2005-04-15 | 2006-04-14 | Cancer treatment by combined inhibition of proteasome and telomerase activities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE553198T1 true ATE553198T1 (de) | 2012-04-15 |
Family
ID=37115747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06750227T ATE553198T1 (de) | 2005-04-15 | 2006-04-14 | Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7998938B2 (de) |
| EP (1) | EP1876893B1 (de) |
| AT (1) | ATE553198T1 (de) |
| WO (1) | WO2006113470A2 (de) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5686493B2 (ja) | 2003-01-24 | 2015-03-18 | ユニバーシティ・オブ・ユタUniversity Of Utah | テロメアの長さを決定することによって死亡の危険性を予測する方法 |
| SI3342425T1 (sl) | 2003-09-09 | 2020-04-30 | Geron Corporation | Modificirani oligonukleotidi za inhibicijo telomeraze |
| US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
| EP1888123B1 (de) | 2005-06-08 | 2013-01-09 | Janssen Biotech, Inc. | Zelltherapie für augendegeneration |
| JP5436860B2 (ja) | 2005-11-09 | 2014-03-05 | オニキス セラピューティクス, インク. | 酵素阻害のための化合物 |
| WO2007127163A2 (en) * | 2006-04-24 | 2007-11-08 | Geron Corporation | Cns-tumor treatment method and composition |
| US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
| NZ573759A (en) | 2006-06-19 | 2012-03-30 | Proteolix Inc | Peptide epoxyketones for proteasome inhibition |
| PT2101789E (pt) | 2006-10-30 | 2015-03-24 | Geron Corp | Inibidor de telomerase combinado e gencitabina para o tratamento de cancro |
| EP2134364B1 (de) * | 2007-03-09 | 2013-02-13 | Geron Corporation | Behandlung von karzinomen mit einer kombination aus egf-pfad- und telomerase-hemmern |
| US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| US9096832B2 (en) | 2007-07-31 | 2015-08-04 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
| EA018973B1 (ru) | 2007-10-04 | 2013-12-30 | Оникс Терапьютикс, Инк. | Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот |
| US8377992B2 (en) * | 2007-10-22 | 2013-02-19 | The Wistar Institute | TRBD-binding effectors and methods for using the same to modulate telomerase activity |
| ATE523585T1 (de) | 2007-11-27 | 2011-09-15 | Lifescan Inc | Differenzierung menschlicher embryonaler stammzellen |
| CA2959401C (en) | 2008-02-21 | 2021-12-07 | Centocor Ortho Biotech Inc. | Methods, surface modified plates and compositions for cell attachment, cultivation and detachment |
| KR101651661B1 (ko) | 2008-06-30 | 2016-08-26 | 얀센 바이오테크 인코포레이티드 | 만능 줄기 세포의 분화 |
| BRPI0919668A2 (pt) | 2008-10-21 | 2018-05-29 | Onyx Therapeutics, Inc. | terapia de combinação com epóxi-cetonas de peptídeo |
| CN102272291B (zh) | 2008-10-31 | 2018-01-16 | 詹森生物科技公司 | 人胚胎干细胞向胰腺内分泌谱系的分化 |
| MX2011004563A (es) | 2008-10-31 | 2011-06-01 | Centocor Ortho Biotech Inc | Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico. |
| PL2366022T3 (pl) | 2008-11-20 | 2016-11-30 | Sposoby i kompozycje do przyłączania i hodowli komórek na podłożach planarnych | |
| PL2366021T3 (pl) | 2008-11-20 | 2017-12-29 | Janssen Biotech, Inc. | Hodowla pluripotencjalnych komórek macierzystych na mikronośnikach |
| JP5840950B2 (ja) | 2008-12-22 | 2016-01-06 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | 単色マルチプレックス定量pcr |
| AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
| ES2693088T3 (es) | 2009-07-20 | 2018-12-07 | Janssen Biotech, Inc. | Diferenciación de células madre embriónicas humanas |
| AU2010276402B2 (en) | 2009-07-20 | 2014-07-03 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| KR20170118969A (ko) | 2009-07-20 | 2017-10-25 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
| AU2010300259A1 (en) * | 2009-10-01 | 2012-04-26 | Janssen Pharmaceutica Nv | Proteasome inhibitors for treating cancer |
| EP2498793B1 (de) | 2009-11-13 | 2019-07-10 | Onyx Therapeutics, Inc. | Oprozomib zur verwendung in der metastasensuppression |
| MX339669B (es) | 2009-12-23 | 2016-06-02 | Janssen Biotech Inc | Diferenciacion de celulas madres embrionarias humanas. |
| AU2010333839C1 (en) | 2009-12-23 | 2016-07-21 | Janssen Biotech Inc. | Differentiation of human embryonic stem cells |
| CN107189979B (zh) | 2010-03-01 | 2021-05-04 | 詹森生物科技公司 | 纯化衍生自多能干细胞的细胞的方法 |
| PH12012501719A1 (en) | 2010-03-01 | 2012-11-12 | Onyx Therapeutics Inc | Compounds for immunoproteasome inhibition |
| KR101986176B1 (ko) | 2010-05-12 | 2019-06-05 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
| WO2012030540A2 (en) | 2010-08-31 | 2012-03-08 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
| AU2011296381B2 (en) | 2010-08-31 | 2016-03-31 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| WO2012030539A2 (en) | 2010-08-31 | 2012-03-08 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| US9388386B2 (en) | 2011-12-22 | 2016-07-12 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into single hormonal insulin positive cells |
| CA2866590A1 (en) | 2012-03-07 | 2013-09-12 | Janssen Biotech, Inc. | Defined media for expansion and maintenance of pluripotent stem cells |
| WO2013184888A1 (en) | 2012-06-08 | 2013-12-12 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into pancreatic endocrine cells |
| US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
| EP2925889B1 (de) | 2012-11-30 | 2018-09-05 | Geron Corporation | Diagnostische marker zur behandlung von zellproliferativen erkrankungen mit telomeraseinhibitoren |
| US9200327B2 (en) | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
| IL280144B2 (en) | 2012-12-07 | 2025-05-01 | Geron Corp | Use of telomerase inhibitors to treat bone marrow culture disorders and bone marrow culture tumors |
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| RU2687379C2 (ru) | 2012-12-31 | 2019-05-13 | Янссен Байотек, Инк. | Суспендирование и кластеризация плюрипотентных клеток человека с целью их дифференцировки в панкреатические эндокринные клетки |
| RU2684215C2 (ru) | 2012-12-31 | 2019-04-04 | Янссен Байотек, Инк. | Способ получения панкреатических эндокринных клеток (варианты) и способ увеличения выхода бета-клеток |
| WO2014105543A1 (en) | 2012-12-31 | 2014-07-03 | Janssen Biotech, Inc. | Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| CN105283559A (zh) | 2013-05-22 | 2016-01-27 | 端粒诊断公司 | 短端粒丰度的量度 |
| EP3868772A1 (de) | 2013-09-30 | 2021-08-25 | Geron Corporation | Phosphorodiamidat-rückgratverbindung für oligonukleotide |
| JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
| JP6588969B2 (ja) | 2014-05-16 | 2019-10-09 | ヤンセン バイオテツク,インコーポレーテツド | 膵内分泌細胞内のmafa発現を強化するための小分子の使用 |
| AU2015372584A1 (en) | 2014-12-30 | 2017-06-29 | Telomere Diagnostics, Inc. | Multiplex quantitative PCR |
| US20180036331A1 (en) * | 2016-03-24 | 2018-02-08 | The Board Of Regents Of The University Of Texas System | Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds |
| JP6705911B2 (ja) | 2016-04-14 | 2020-06-03 | ヤンセン バイオテツク,インコーポレーテツド | 多能性幹細胞の中腸内胚葉細胞への分化 |
| EP3318276A1 (de) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Zusammensetzungen aus einem telomerase-hemmer und einem bcl-2-hemmer zur behandlung von blutkrebs |
| WO2019023667A1 (en) | 2017-07-28 | 2019-01-31 | Janssen Biotech, Inc. | METHODS OF TREATING MYELODYSPLASTIC SYNDROME |
| EP3887537A4 (de) | 2018-11-29 | 2023-04-12 | Geron Corporation | Verfahren zur behandlung des myelodysplastischen syndroms |
| JP2023532199A (ja) * | 2020-06-17 | 2023-07-27 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | プロテアソーム阻害剤治療のためのバイオマーカーに基づく患者選択 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
| US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
| US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
| US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
| US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
| US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
| JP5583882B2 (ja) | 2003-06-23 | 2014-09-03 | テロメラーゼ アクティベーション サイエンシーズ, インコーポレイテッド | テロメラーゼ活性を増大させるための組成物および方法 |
| SI3342425T1 (sl) * | 2003-09-09 | 2020-04-30 | Geron Corporation | Modificirani oligonukleotidi za inhibicijo telomeraze |
-
2006
- 2006-04-14 WO PCT/US2006/014137 patent/WO2006113470A2/en not_active Ceased
- 2006-04-14 US US11/918,581 patent/US7998938B2/en active Active
- 2006-04-14 EP EP06750227A patent/EP1876893B1/de not_active Expired - Lifetime
- 2006-04-14 AT AT06750227T patent/ATE553198T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006113470A2 (en) | 2006-10-26 |
| US7998938B2 (en) | 2011-08-16 |
| WO2006113470A3 (en) | 2006-12-14 |
| EP1876893A2 (de) | 2008-01-16 |
| US20100010064A1 (en) | 2010-01-14 |
| EP1876893B1 (de) | 2012-04-11 |
| EP1876893A4 (de) | 2010-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006113470A3 (en) | Cancer treatment by combined inhibition of proteasome and telomerase activities | |
| WO2008054711A3 (en) | Combined telomerase inhibitor and gemcitabine for the treatment of cancer | |
| PL1660507T5 (pl) | Inhibitory proteazomu oraz sposoby ich stosowania | |
| EA201391705A1 (ru) | Триазолпиридиновые ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i | |
| IL184678A0 (en) | Proteasome inhibitors and methods of using the same | |
| SG157365A1 (en) | Compositions and methods for treating neoplastic diseases | |
| MX2010006154A (es) | Tratamiento del cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de la poli-adp-ribosa-polimerasa. | |
| EA200800006A1 (ru) | Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i | |
| CR9672A (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores | |
| WO2005110477A3 (en) | Combination therapies for cancer and proliferative angiopathies | |
| WO2008100562A3 (en) | Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells | |
| CR11486A (es) | Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales | |
| EA200900571A1 (ru) | Композиции chk1 ингибиторов | |
| WO2005016859A3 (en) | Proteasome inhibitors and methods of using the same | |
| MY160041A (en) | Compositions and methods for treating parasitic infections | |
| WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| SG164368A1 (en) | Treatment of cancer | |
| TR200600899T2 (tr) | İzoksazolin halkası içeren kaspaz inhibitörleri | |
| WO2008112129A3 (en) | Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors | |
| MX366119B (es) | Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2. | |
| MY162518A (en) | Proteasome inhibitors and methods of using the same | |
| WO2007059154A3 (en) | Treatment of cancers with acquired resistance to kit inhibitors | |
| WO2006113426A3 (en) | Cancer treatment by combined inhibition of telomerase and tubulin activities | |
| WO2006124904A3 (en) | Cancer treatment by combined inhibition of telomerase and hsp90 activities | |
| WO2006081371A3 (en) | Combination therapy with triterpenoid compounds and proteasome inhibitors |